



ASX ANNOUNCEMENT

24 April 2025

## Completion of Entitlement Offer

**Melbourne, Australia, 24 April 2025:** Chimeric Therapeutics Limited (ASX:CHM) (**Chimeric or Company**) on 18 March 2025 announced the investor participation of a non-renounceable entitlement offer (**Entitlement Offer**) to raise up to \$3.2 million. Under the Entitlement Offer, eligible shareholders were able to subscribe for 2 new fully paid ordinary shares in Chimeric (**New Shares**), and 1 new attaching option for every New Share issued (**New Option**), for every 5 existing ordinary shares.

The New Shares will have an issue price of \$0.005 and the New Options will have an exercise price of \$0.008 per New Option and an expiry date of 19 December 2025<sup>1</sup>.

On 3 April 2025, Chimeric extended the closing date of the Entitlement Offer to 5pm (Sydney time) on 22 April 2025. Chimeric received valid applications under the Entitlement Offer for 197,203,052 New Shares, raising an amount of approximately \$1 million. 365 shareholders participated in the Entitlement Offer.

**Chimeric's CEO Dr Rebecca McQualter** said: "we are pleased with the continued support shown by shareholders in our recent rights issue. This additional funding provides us with further runway to progress our programs."

Issue and allotment of the New Shares and New Options will occur on 30 April 2025, and ASX trading of the New Shares and New Options is expected to commence on 1 May 2025.

A shortfall of approximately 450,857,654 New Shares and 450,857,654 New Options (representing an amount of approximately \$2.2 million) remains. The Company can place the shortfall in accordance with the ASX listing rules within 3 months of the closing date to the Entitlement Offer.

PAC Partners and Taylor Collison acted as joint lead manager to the Entitlement Offer and any shortfall placement.

The Directors thank all eligible shareholders who participated in the Entitlement Offer for their continuing support.

---

<sup>1</sup> Eligible shareholders must, at the issuance date of New Options, hold at least the number of New Shares they subscribed for under the Entitlement Offer.



## **ABOUT CHIMERIC THERAPEUTICS**

Chimeric Therapeutics, a clinical stage cell therapy company and an Australian leader in cell therapy, is focused on bringing the promise of cell therapy to life for more patients with cancer. To bring that promise to life for more patients, Chimeric's world class team of cell therapy pioneers is focused on the discovery, development, and commercialization of the most innovative and promising cell therapies.

Chimeric currently has a diversified portfolio that includes first in class autologous CAR-T cell therapies and best in class allogeneic NK cell therapies. Chimeric assets are being developed across multiple different disease areas in oncology with 4 clinical stage programs.

CHM CDH17 is a first-in-class, 3rd generation CDH17 CAR-T invented at the world-renowned cell therapy centre, the University of Pennsylvania (Penn) in the laboratory of Dr. Xianxin Hua, professor in the Department of Cancer Biology in the Abramson Family Cancer Research Institute at Penn. Preclinical evidence for CDH17 CAR-T was published by Dr. Hua and colleagues in 2022 in Nature Cancer demonstrating complete eradication of tumours in 7 types of cancer in mice. CHM CDH17 is currently being studied in a phase 1/2 clinical trial in gastrointestinal and neuroendocrine tumours that was initiated in 2024.

CHM CLTX is a novel and promising CAR-T therapy developed for the treatment of patients with solid tumours. CLTX CAR-T is currently being studied in a phase 1B clinical trial in recurrent / progressive glioblastoma. Positive preliminary data from the investigator-initiated phase 1A trial in glioblastoma was announced in October 2023.

CHM CORE-NK is a potentially best-in-class, clinically validated NK cell platform. Data from the complete phase 1A clinical trial was published in March 2022, demonstrating safety and efficacy in blood cancers and solid tumours. Based on the promising activity signal demonstrated in that trial, two additional Phase 1B clinical trials investigating CORE-NK in combination regimens have been initiated. From the CORE-NK platform, Chimeric has initiated development of new next generation NK and CAR NK assets.

*Authorised on behalf of the Chimeric Therapeutics board of directors by Executive Chariman Paul Hopper.*

## **Contact**

Investors

Dr Rebecca McQualter

Chief Executive Officer

Chimeric Therapeutics

E: [investors@chimerictherapeutics.com](mailto:investors@chimerictherapeutics.com)

W: [www.chimerictherapeutics.com](http://www.chimerictherapeutics.com)



Media

Matthew Wright

NWR Communications

T: +61 451 896 420

E: [matt@nwrcommunications.com.au](mailto:matt@nwrcommunications.com.au)